Naoto T Ueno: Findings on Anthracyclines in HER2-Positive Inflammatory Breast Cancer
Naoto T Ueno, Director of the University of Hawaii Cancer Center, shared a post on X:
“A study finds no difference in pCR between regimens with or without anthracyclines in HER2-positive inflammatory breast cancer (IBC). But those on anthracyclines had better disease control. More research needed.”
Title: Neoadjuvant HER2-targeted regimens with or without anthracyclines for HER2-positive inflammatory breast cancer: a multicenter retrospective study
Authors: Toshiaki Iwase, Nithya Sridhar, Megumi Kai, Wenli Dong, Yu Shen, Savitri Krishnamurthy, Anthony Lucci, H. T. Carisa Le-Petross, Azadeh Nasrazadani, Sadia Saleem, Rachel M. Layman, Vincente Valero, Debasish Tripathy, Wendy A. Woodward, Yee Chung Cheng, Faina Nakhlis, Jenifer R. Bellon, Filipa Lynce, Naoto T. Ueno
Read the Full Article.
More posts featuring Naoto T Ueno.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023